Cell Line and Membrane Market

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives


• Reasons for Doing This Study


• Scope of Report


• Information Sources


• Methodology


• Geographic Breakdown


• Analyst's Credentials


• Custom Research


• Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

• Introduction


• Market Potential


• Regulatory Framework


• United States


• European Union


• China


• India


• Japan


• Brazil


• Investment Analysis


• Industry Growth Drivers


• Advancement in Technologies Accelerating the Scale-up of Cell Lines


• High Investment in Cell Culture Technology


• Increasing Adoption of Cell Line Technologies in Cell-Based Assays


• Surging Demand for Antibody Production


• High Investments by Pharmaceutical and Biotechnology Companies in Drug Development

Chapter 4 Market Breakdown by Product

• Type of Cell Line


• Development of Cell Lines and Cell Culture


• Immunotherapy Cell Lines


• Ion Channel Cell Lines


• GPCR Cell Lines


• Cell Signaling Pathway Cell Lines


• Gene Knockout Cell Lines


• Cancer Cell Lines


• Others


• Type of Cell Membrane


• Natural


• Synthetic

Chapter 5 Market Breakdown by End User

• Biopharmaceutical Companies


• Contract Research Organizations (CROs)


• Academic and Research Institutes


• Forensic Science Laboratories


• Food and Beverage Companies


• Application of Cell Lines and Cell Cultures


• The Benefits of Using Plant Cell Lines:


• Microbes for Food and Beverage Production


• Cell Lines in Clean Meat


• Diagnostic Centers


• Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research in Diagnostic Centers


• Cell Membrane Proteomics Can Potentially Identify Breast Cancer


• Others

Chapter 6 Market Breakdown by Application

• Drug Discovery and Development


• Application of Cell Line and Membrane in Drug Discovery and Development Process


• Surging Utilization of Cell Lines in Cancer Pharmagenomics


• Clinical Trials


• Basic Research


• Benefits of Cell Line in Research


• Toxicity Screening


• Biopharmaceutical Production


• The Use of Human Cell Line for Biopharmaceutical Production


• The Use of CHO Cells for Biopharmaceutical Production


• Driver


• Drug Screening


• Driver


• Forensic Testing


• Cell Line Authentication


• Tissue Engineering


• Stem Cell Applications in Tissue Engineering


• Driver

Chapter 7 Market Breakdown by Region

• North America


• U.S.


• Canada


• Europe


• U.K.


• Germany


• France


• Spain


• Rest of Europe


• Asia-Pacific


• China


• India


• Japan


• Australia


• ROAPAC


• RoW (Rest of the World)


• Latin America


• Middle East and Africa

Chapter 8 Cell Line and Membrane Market Industry Structure

• Procurement of Raw Materials


• Quality


• Terms and Conditions


• Cost Effective Components


• Manufacturing/Development Process


• End Users


• Factors Affecting Cell Line and Membrane Market


• Innovation within the Industry


• Various Gene Engineering Approaches


• Advancements in Cell Lines for Cancer-Based Therapies


• CAR T-Cell Lines and Immune Checkpoint Inhibitors


• Autologous vs. Allogenic Cells Manufacturing Process


• Competitive Analysis

Chapter 9 Company Profiles

• Abzena


• ACM Biolabs


• ATCC


• BD Biosciences


• Bioivt


• Catalent Inc.


• Cell Biolabs Inc.


• Corning Inc.


• Creative Biolabs


• Etubics Corp.


• GE Healthcare


• Ixcells Biotechnologies


• Lonza Group Ltd.


• MI Bioresearch Inc.


• Merck Millipore


• Miltenyi Biotec


• Novus Biologicals


• Rockland Immunochemicals Inc.


• Quidel Corp.


• Sartorius


• Selexis Sa


• Thermo Fisher Scientific


• Wuxi Apptec

List of Tables
Summary Table: Global Market for Cell Line and Membrane, by Product, Through 2023
Table 1: Investment Analysis
Table 2: Investments in Cell Culture Technology
Table 3: Regional Analysis of Studies on Antibodies
Table 4: Total Global Pharmaceutical R&D Spending, 2015-2022
Table 5: Global Cell Line and Membrane Market, by Product, Through 2023
Table 6: Key Sources and Description of Biological Contamination of Cell Lines and Membranes
Table 7: Some Key Mammalian and Insect Cell Cultures
Table 8: List of Animal Cell Lines Used in Research
Table 9: Global Cell Line Market, by Type, Through 2023
Table 10: Global Cell Line Market, by Region, Through 2023
Table 11: NCI-60 Cancer Cell Lines
Table 12: Most Common Cancers, by Type, 2018
Table 13: Research Grants, by Cancer Type, August 2018
Table 14: Global Cell Membrane Market, by Type, Through 2023
Table 15: Global Pharmaceutical R&D Spending, 2015-2022
Table 16: Global Cell Membrane Market, by Region, Through 2023
Table 17: Global Cell Line and Membrane Market, by End User, Through 2023
Table 18: Global Biopharmaceutical Companies Market, by Region, Through 2023
Table 19: Cell Lines Used in the Production of Biopharmaceuticals
Table 20: Global Growth in Pharmaceutical Market, 2015 and 2020
Table 21: Global Biologics Spending, 2011 and 2016
Table 22: Global Biosimilars Spending, 2011 and 2016
Table 23: Global Contract Research Organizations (CROs) Market, by Region, Through 2023
Table 24: Drug Development, by CRO, 2017 and 2018
Table 25: Global Academic and Research Institutes Market, by Region, Through 2023
Table 26: Cell Lines Research and Development in Academic and Research Institutes, 2017 and 2018
Table 27: Global Prevalence of Dementia, 2015-2050
Table 28: Global Forensic Science Laboratories Market, by Region, Through 2023
Table 29: Global Food and Beverage Companies Market, by Region, Through 2023
Table 30: Microbial Strains Used in Food and Beverage Industries
Table 31: Global Diagnostic Centers Market, by Region, Through 2023
Table 32: Global Other End Users Market, by Region, Through 2023
Table 33: Global Cell Line and Membrane Market, by Application, Through 2023
Table 34: Global Drug Discovery and Development Market, by Region, Through 2023
Table 35: International Cancer Research Projects Share, by Region, 2017-2018
Table 36: American Chemical Society Grants, by Cancer Type, 2018
Table 37: Investment in Cancer Research in Canada, by Cancer Type, 2016
Table 38: Drugs in Development, by Disease Type, 2017
Table 39: Pharmaceutical Spending, by Country, 2016
Table 40: Global Basic Research Market, by Region, Through 2023
Table 41: U.S. R&D Funding Share, 2016
Table 42: Global Toxicity Screening Market, by Region, Through 2023
Table 43: Member Companies of the Pharmaceutical Research and Manufacturers of America R&D Investments (U.S.), 2005-2016
Table 44: Investments in Personalized Medicine, 2017 and 2018
Table 45: Global Biopharmaceutical Production Market, by Region, Through 2023
Table 46: U.S. Food and Drug Administration-Approved Protein Therapeutics, 2015-2016
Table 47: Comparison of Human Cell Lines with Other Expression Systems in the Production of Therapeutic Proteins
Table 48: Monoclonal Antibodies Approved by the European Medical Agency and Food and Drug Administration for Therapeutic Use Status, 2015-2017
Table 49: Pharmaceutical R&D Expenditure in Europe, the U.S. and Japan, 2010 and 2015
Table 50: Global Drug Screening Market, by Region, Through 2023
Table 51: Advantages and Disadvantages of the Use of Cancer Cell Lines as Models in Cancer Research
Table 52: Estimated New Cases of Leukemia, Lymphoma, and Myeloma, 2018
Table 53: Global Forensic Testing Market, by Region, Through 2023
Table 54: Current Status of SNP, STR, and DNA Barcode Technologies as Standard Methods for Assessing the Identity of Cell Lines from Different Species
Table 55: Global Tissue Engineering Market, by Region, Through 2023
Table 56: NIH Spending Trend on Stem Cell Research, 2015-2018
Table 57: Global Cell Line and Membrane Market, by Region, Through 2023
Table 58: North American Cell Line and Membrane Market, by Country, Through 2023
Table 59: NIH Spending on Stem Cell Research, 2013-2016
Table 60: North American Cell Line and Membrane Market, by Product, Through 2023
Table 61: NIH Funding for CRISPR-Related Research, 2006-2016
Table 62: North American Cell Line and Membrane Market, by End User, Through 2023
Table 63: Net Spending on Biologics in the U.S., 2013-2017
Table 64: North American Cell Line and Membrane Market, by Application, Through 2023
Table 65: Percentage Increase of Spending on Biologics in Canada, 2011-2016
Table 66: European Cell Line and Membrane Market, by Country, Through 2023
Table 67: Pharmaceutical Industry R&D Expenditures in Selected European Countries
Table 68: Cumulative Spending on Biosimilar Medicines in the EU5, 2016-2020
Table 69: European Cell Line and Membrane Market, by Product, Through 2023
Table 70: U.K. Pharmaceutical R&D Expenditures, 2014 and 2015
Table 71: European Cell Line and Membrane Market, by End User, Through 2023
Table 72: European Cell Line and Membrane Market, by Application, Through 2023
Table 73: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2016
Table 74: Asia-Pacific Cell Line and Membrane Market, by Country, Through 2023
Table 75: Asia-Pacific Cell Line and Membrane Market, by Product, Through 2023
Table 76: Studies Recruiting Under Phase IV, Based on Cell Line
Table 77: Number of People with Cancer in China, 2010-2016
Table 78: Asia-Pacific Cell Line and Membrane Market, by Application, Through 2023
Table 79: Growth in Biotech Industry in India, 2010-2017
Table 80: Some of the Approved Biosimilar Products in India
Table 81: Growing Number of Cancer Patients in India, 2010-2016
Table 82: Asia-Pacific Cell Line and Membrane Market, by End User, Through 2023
Table 83: R&D Spending in India, by Top Pharmaceutical Companies, 2016
Table 84: List of Biotech Companies Supported by Osaka University in Cell Culture
Table 85: Estimated Most Common Cancer Diagnosed, by Type, 2018
Table 86: Commonly Diagnosed Cancers in Australia, 2017
Table 87: Rest of the World Cell Line and Membrane Market, by Country, Through 2023
Table 88: Rest of the World Cell Line and Membrane Market, by Product, Through 2023
Table 89: Rest of the World Cell Line and Membrane Market, by End User, Through 2023
Table 90: Rest of the World Cell Line and Membrane Market, by Application, Through 2023
Table 91: Global Suppliers to Cell Line and Membrane Market
Table 92: Some of the Major Cell Line and Membrane Companies
Table 93: FDA Center for Drug Evaluation and Research Approved Biologics Based on Cell Lines, 2015
Table 94: Some CRISPR-Cas-Based Gene Editing Techniques Used for Manipulation of Various Organisms
Table 95: CAR T-Cell Therapy in Immuno-Oncology Medicine Development, 2017
Table 96: Global CAR T-Cell Therapy Market, by Region, Through 2023
Table 97: Global Immune Checkpoint Inhibitor Therapy Market, by Region, Through 2023
Table 98: FDA-Approved Immune Checkpoint Inhibitors
Table 99: Global Distribution of All Studies on Immune Checkpoint Inhibitors, by Region/Country
Table 100: Autologous vs. Allogenic Cells Manufacturing Process
Table 101: Abzena: Product Portfolio
Table 102: Abzena: Recent Developments
Table 103: ACM Biolabs: Product Portfolio
Table 104: ACM Biolabs: Recent Developments, January 2018 to December 2018
Table 105: ATCC: Product Portfolio
Table 106: ATCC: Recent Developments, 2015 to September 2018
Table 107: BD Biosciences: Product Portfolio
Table 108: BioIVT: Product Portfolio
Table 109: BioIVT: Recent Developments, 2015 to September 2018
Table 110: Catalent Inc.: Product Portfolio
Table 111: Catalent Inc.: Recent Developments, 2015 to September 2018
Table 112: Cell Biolabs Inc.: Product Portfolio
Table 113: Corning Inc.: Product Portfolio
Table 114: Creative Biolabs: Product Portfolio
Table 115: Etubics Corp.: Product Portfolio
Table 116: Etubics Corp.: Recent Developments, 2015 to September 2018
Table 117: GE Healthcare: Product Portfolio
Table 118: GE Healthcare: Recent Developments, 2015 to September 2018
Table 119: iXCells Biotechnologies: Product Portfolio
Table 120: Lonza Group Ltd.: Product Portfolio
Table 121: Lonza Group Ltd.: Recent Developments, 2015 to September 2018
Table 122: MI Bioresearch Inc.: Product Portfolio
Table 123: Merck Millipore: Product Portfolio
Table 124: Merck Millipore: Recent Developments, 2015 to September 2018
Table 125: Miltenyi Biotec: Product Portfolio
Table 126: Miltenyi Biotec: Recent Developments, 2015 to September 2018
Table 127: Novus Biologicals: Product Portfolio
Table 128: Novus Biologicals: Recent Developments, 2015 to September 2018
Table 129: Rockland Immunochemicals Inc.: Product Portfolio
Table 130: Rockland Immunochemicals Inc.: Recent Developments, 2015 to September 2018
Table 131: Quidel Corp.: Product Portfolio
Table 132: Quidel Corp.: Recent Developments, 2015 to September 2018
Table 133: Sartorius: Product Portfolio
Table 134: Selexis SA: Product Portfolio
Table 135: Thermo Fisher Scientific: Product Portfolio
Table 136: Thermo Fisher Scientific: Recent Developments, 2015 to September 2018
Table 137: WuXi AppTec: Product Portfolio
Table 138: WuXi AppTec: Recent Developments, 2015 to June 2018

List of Figures
Summary Figure: Global Market for Cell Line and Membrane, by Product, 2017-2023
Figure 1: Types of Cell Line Technologies
Figure 2: Total Global Pharmaceutical R&D Spending, 2015-2022
Figure 3: PhRMA Member Company R&D Expenditures, 2010 and 2016
Figure 4: Process of Deriving a Cell Line
Figure 5: Type of Cell Lines
Figure 6: Process of Growing Cell Lines and Delivering to Patients
Figure 7: Production Process of Ion Channel Cell Line
Figure 8: GPCR Cell Line Development Process
Figure 9: Applications of Cell Signaling Pathway Cell Lines
Figure 10: Generation of Knockout Cell Lines
Figure 11: Most Common Cancers, by Type, 2018
Figure 12: Production Process of Monoclonal Antibodies from Hybridoma Cell Lines
Figure 13: Global Pharmaceutical R&D Spending, 2015-2022
Figure 14: Common Benefits of Human Cell Lines in the Production of Therapeutic Proteins
Figure 15: Biopharmaceutical Production Using Mammalian Cells
Figure 16: Global Growth in Pharmaceutical Market, 2015 and 2020
Figure 17: Global Biologics Spending, 2011 and 2016
Figure 18: Global Biosimilars Spending, 2011 and 2016
Figure 19: Cell Lines and Membranes Application in Academic and Research Institutes
Figure 20: Global Prevalence of Dementia, 2015-2050
Figure 21: Advantages of Short Tandem Repeat Profiling in Cell Line Authentication
Figure 22: Workflow for Authentication of Cell Lines
Figure 23: Clean Meat Development Process Through Cell Lines
Figure 24: Meat Consumption, 2015-2027
Figure 25: Workflow Outlines Process of Obtaining Plasma Membrane Proteome of Multiple BC Cell Lines
Figure 26: Storage of Cell Lines in Cell Bank
Figure 27: Major Factors Driving the Growth of the Cell Line and Membrane Market, by Application
Figure 28: International Cancer Research Projects Share, by Region, 2017-2018
Figure 29: Drugs Share in Development, by Disease Type, 2017
Figure 30: Pharmaceutical Spending, by Country, 2016
Figure 31: U.S. R&D Funding Share, 2016
Figure 32: Member Company of Pharmaceutical Research and Manufacturers of America R&D Investment (U.S.), 2005-2016
Figure 33: Pharmaceutical R&D Expenditure in Europe, U.S. and Japan, 2010 and 2015
Figure 34: STR Analysis of Cell Lines
Figure 35: The Basic Materials and Processes Needed for Tissue Engineering Technologies
Figure 36: NIH Spending Trend on Stem Cell Research, 2015-2018
Figure 37: NIH Spending on Stem Cell Research, 2013-2016
Figure 38: Net Spending on Biologics in the U.S., 2013-2017
Figure 39: Pharmaceutical Industry R&D Expenditure in Selected European Countries
Figure 40: U.K. Pharmaceutical R&D Expenditures, 2014 and 2015
Figure 41: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2016
Figure 42: Number of People with Cancer in China, 2010-2016
Figure 43: Growth in Biotech Industry in India, 2010-2017
Figure 44: Growing Number of Cancer Patients in India, 2010-2016
Figure 45: R&D Spending in India, by Top Pharmaceutical Companies, 2016
Figure 46: Japan Pharmaceuticals Industry, 2010-2015
Figure 47: Estimated Most Common Cancer Diagnosed, by Type, 2018
Figure 48: Industry Structure of the Cell Line and Membrane Market
Figure 49: Cell Line Development Flow chart
Figure 50: CAR T-Cell Therapy Mechanism
Figure 51: Global CAR T-Cell Therapy Market, by Region, 2017-2023
Figure 52: Global Immune Checkpoint Inhibitor Therapy Market, by Region, 2017-2023
Figure 53: Global Distribution of All Studies on Immune Checkpoint Inhibitors, by Region/Country
Figure 54: Competitive Analysis Share for Cell Line and Membrane Market, by Strategies

Companies Mentioned

• Abzena


• ACM Biolabs


• ATCC


• BD Biosciences


• Bioivt


• Catalent Inc.


• Cell Biolabs Inc.


• Corning Inc.


• Creative Biolabs


• Etubics Corp.


• GE Healthcare


• Ixcells Biotechnologies


• Lonza Group Ltd.


• Merck Millipore


• MI Bioresearch Inc.


• Miltenyi Biotec


• Novus Biologicals


• Quidel Corp.


• Rockland Immunochemicals Inc.


• Sartorius


• Selexis Sa


• Thermo Fisher Scientific


• Wuxi Apptec